Le Lézard
Classified in: Science and technology
Subject: Personnel

Belden's Hiran Bhadra Promoted to Sr. Vice President, Strategy & Technology


Belden Inc. (NYSE: BDC), a leading global supplier of digitization and network infrastructure solutions, announced today the promotion of Hiran Bhadra to the role of Sr. Vice President, Strategy & Technology, reporting to CEO Ashish Chand.

In his expanded role as the CTO of the company, he will continue to shape Belden's technology strategy while expanding his focus to reinforce the company's commitment to technology and innovation. He will also work to drive scalable technology solutions in automation and smart infrastructure, while working closely with business segments to ensure the company's technology solutions align with business objectives.

"Belden is building the future by connecting people, information, and ideas to unlock possibilities," Chand said. "We understand today's innovation is tomorrow's necessity. Hiran's promotion and expanded focus is a further step toward ensuring our broad portfolio of high-quality products allows us to build solutions and create financial strength to invest in innovation while aligning with our One Belden strategy."

Bhadra joined Belden in 2022 as part of the Senior Leadership team. During his time at Belden, he has led the company's strategy and technology efforts while also championing the benefits of emerging technologies to customers, vendors and partners. According to Chand, Bhadra will continue to lead planning efforts to migrate the company from a products-based supplier to a solutions-focused organization with a strong focus on core networking product technologies and data engineering capabilities. Prior to Belden, Hiran worked as a senior partner in consulting organizations such as Accenture and KPMG with a focus on manufacturing and digital transformation.

About Belden

Belden Inc. delivers the infrastructure that makes the digital journey simpler, smarter and secure. We're moving beyond connectivity, from what we make to what we make possible through a performance-driven portfolio, forward-thinking expertise and purpose-built solutions. With a legacy of quality and reliability spanning 120-plus years, we have a strong foundation to continue building the future. We are headquartered in St. Louis and have manufacturing capabilities in North America, Europe, Asia, and Africa. For more information, visit us at www.belden.com; follow us on Facebook, LinkedIn and Twitter.

Belden and the Belden logo are trademarks or registered trademarks of Belden Inc. or its affiliated companies in the United States and other jurisdictions. Belden and other parties may also have trademark rights in other terms used herein.


These press releases may also interest you

at 21:09
On June 29, the "Gather Great Wisdom to Shape the Future of Intelligent Manufacturing?Special Exhibition on Design Intelligence and High Quality Development", hosted by the China Academy of Art (CAA), opened at the National Museum of China in...

at 20:55
Intermap Technologies ("Intermap" or the "Company"), a global leader in 3D geospatial products and intelligence solutions, announces a new financing. The Company is offering up to a maximum of 4,300,000 Class "A" common shares of the Company...

at 20:45
"The Classic Quotes by Xi Jinping," a multilingual TV show produced by China Media Group, aired in Kazakhstan on Tuesday after Chinese...

at 20:07
Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing both first-in-class and best-in-class therapies for hematological malignancies, announced today that on July 2, 2024, in relation to...

at 20:05
Enterprises in Asia Pacific are moving toward software-defined networking (SDN) to make communication more secure and resilient and speed up business decision-making, according to a new research report published today by Information Services Group...

at 20:00
Atara Biotherapeutics, Inc. , a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Pascal...



News published on and distributed by: